Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.
about
Venous thromboembolic diseaseManagement of antithrombotic therapy during cardiac implantable device surgeryMarine Non-Glycosaminoglycan Sulfated Glycans as Potential PharmaceuticalsModels for thrombin generation and risk of diseaseAnticoagulation drug therapy: a reviewMinimizing bleeding risk in patients receiving direct oral anticoagulants for stroke preventionPharmacology of anticoagulants used in the treatment of venous thromboembolismGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismNew oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic eventsReal-Time Label-Free Embolus Detection Using In Vivo Photoacoustic Flow CytometrySelecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.In vitro and in vivo characterization of a reversible synthetic heparin analog.Saddle pulmonary embolism in a cancer patient with thrombocytopenia: a treatment dilemma.Management of anticoagulant-related intracranial hemorrhage: an evidence-based review.Role of factor xa inhibitors in cancer-associated thrombosis: any new data?A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor XaExopolysaccharides produced by marine bacteria and their applications as glycosaminoglycan-like moleculesDirect oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.Discovery of an intrinsic tenase complex inhibitor: Pure nonasaccharide from fucosylated glycosaminoglycanAllosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran.Managing patients taking edoxaban in dentistryA complicated case of anticoagulation.IVC filters may prevent fatal pulmonary embolism in musculoskeletal tumor surgery.Factor XI as a Therapeutic Target.The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.Controversies of anticoagulation reversal in life-threatening bleeds.The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy.Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.Thromboprophylaxis, bleeding and post-operative prosthetic joint infection in total hip and knee arthroplasty: a comprehensive literature review.Sulodexide in the treatment of chronic venous disease.Reversal of antithrombotic agents.Emergency management of bleeding associated with old and new oral anticoagulants.Clinical management of rivaroxaban-treated patients.Point-of-care coagulation management in intensive care medicine.Current state of knowledge on oral anticoagulant reversal using procoagulant factors.Nano-antidotes for drug overdose and poisoning.Glycosaminoglycan-based resorbable polymer composites in tissue refurbishment.The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.
P2860
Q24631121-87673712-E6C6-4E57-8B7E-E6A77E2FF14CQ26746160-0F28494E-3CFA-4445-B86F-8306C00D7334Q26774227-ACBD15C2-FD48-4E78-B827-0E82A9A5A869Q27013171-52AAF882-628C-411A-86D2-78C3FCDBD42CQ27021871-C03B696D-0AA4-4AD1-A160-1856E2369ABAQ28069809-FF9E4A00-A950-48AC-A207-845D3EED03DFQ28078967-41CD1893-9547-407F-B024-A736E79DC560Q28079081-C698F99B-18F2-4B0E-A10A-59CF94C777F6Q28080616-0D758124-4358-4A4E-A50E-F2B4934C5066Q30381707-8A918233-6A8E-42F4-A2FA-622408DDF0AEQ30438893-35C13C74-11E0-457D-A442-7B71A62CFDFEQ30710756-E23B8691-A74F-492B-9DE5-C3F80789967CQ33393653-B22ADDC7-4737-44B3-8963-E5417AAFF6CEQ33750215-AA7A9F74-12EC-4BFD-9315-CFE59FE5F89FQ34052232-0C138378-377A-4CAE-9FBD-0720B82EF225Q34330708-45FE8604-E2B9-4A9F-BFF4-9B2053846A06Q35360491-F9516EC9-1633-4BDE-B9AB-2D50F6716863Q35746798-E50EF66B-6750-4BDF-9CB6-5995BBC215B8Q35845738-AA037573-D2D5-4E23-AEA2-DBA6E87FCFCBQ35920828-DEDC6495-A331-4B01-824E-A4D56D8D266AQ36121888-0C2879EB-C21D-4AA9-BD43-DF8143FD14FFQ36283736-4F0487E0-521B-4446-8A15-BE0EECBAA7DDQ36283741-CC1794AA-7034-47B3-A3DE-506A5FDEAEE3Q36704638-6C5544FC-DFA4-4E3C-A425-DE7EDE50C071Q37011663-ABB41E17-60F3-4A4E-B109-6C21EC800D61Q37033749-83F06D7C-5384-4FD3-A695-1B6049F70031Q37316352-6E87F5DD-38E6-4B93-8DD0-E0C7774DA600Q37867279-AD4266FD-1912-42CF-9F31-802C2269D8F1Q37873969-8BE49298-F6BD-4D80-A01E-A30E36DD4471Q37897674-A5ED91CD-4F76-43A6-A258-55931BB24CA6Q37973405-239D5C62-63F4-44EA-9243-FB9DF8093F71Q37983620-99E161F6-D724-4E9B-9B2B-2165DEA3F58FQ37998377-E17E6430-507E-42B3-AA6B-C0197CADA20AQ38027479-5F11FA32-1F8B-4FD1-9CDB-9338AF1C32AAQ38081946-8EE41A95-20BC-4AF6-8006-133C170CE83DQ38091152-4119CB35-1EB4-42D7-8A07-EEC701841991Q38108527-EA8EF573-7B9B-44B4-BD50-62AEC2E834A0Q38515174-E0CB8431-0F9A-469F-B74A-324A937146EDQ38722790-A8FC3B18-945E-469B-B1F0-E6742510EBD6Q38956551-D0F4FBD3-A9A6-45B5-9026-008961CF651A
P2860
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@ast
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@en
type
label
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@ast
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@en
prefLabel
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@ast
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@en
P1433
P1476
Bleeding risk and the manageme ...... s on new anticoagulant agents.
@en
P2093
Mark A Crowther
P304
P356
10.1182/BLOOD-2007-10-120543
P407
P577
2008-02-28T00:00:00Z